Vir Biotechnology (VIR)
NASDAQ:VIR
Top Page
Vir Biotechnology
(NASDAQ:VIR)
Select Model
Select Model
Rating:63Neutral
Price Target:
$9.50
▼(-3.36% Downside)
Action:ReiteratedDate:03/05/26
The score is held back primarily by weak financial performance (large losses and ongoing cash burn), partially offset by strong earnings-call fundamentals (Astellas partnership, clearer runway guidance, and encouraging early clinical signals) and constructive technical uptrend. Valuation remains constrained by negative earnings, while corporate events add liquidity but with dilution.
Positive Factors
Strategic Astellas collaboration
A large, structured partnership materially de-risks VIR-5500 development by providing significant upfront capital, cost-sharing for global development, and ex-U.S. commercialization reach. This improves funding stability and long-term commercial optionality for Vir's oncology franchise.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow weakens financial flexibility and raises the probability of future dilutive financing if milestones slip. Continued cash burn constrains the firm's ability to self-fund multiple late‑stage programs and increases execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Astellas collaboration
A large, structured partnership materially de-risks VIR-5500 development by providing significant upfront capital, cost-sharing for global development, and ex-U.S. commercialization reach. This improves funding stability and long-term commercial optionality for Vir's oncology franchise.
Read all positive factors
Vir Biotechnology (VIR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.57B
Dividend YieldN/A
Average Volume (3M)3.50M
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue Growth-78.55%
EPS Growth7.74%
CountryUS
Employees408
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.31
Shares Outstanding159,811,400
10 Day Avg. Volume1,625,418
30 Day Avg. Volume3,500,915
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue21.46
Enterprise Value/Gross Profit21.47
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$20.86Price Target Upside112.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.04
Revenue Forecast (FY)$110.61M
Vir Biotechnology Business Overview & Revenue Model
Company Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infecti...
How the Company Makes Money
Vir Biotechnology generates revenue primarily through the development and commercialization of its therapeutic products. Key revenue streams include sales of approved products, licensing agreements, and collaborations with pharmaceutical companies...
Vir Biotechnology Key Performance Indicators (KPIs)
Any
Revenue by Segment
Provides insight into which business areas are driving sales, highlighting strengths and potential vulnerabilities in the company's revenue streams.
Provides insight into which business areas are driving sales, highlighting strengths and potential vulnerabilities in the company's revenue streams.
Data provided by:
The Fly
The FlyVir Biotechnology Earnings Call Summary
Earnings Call Date:Feb 23, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call conveyed predominantly positive momentum: a strategically valuable collaboration with Astellas that provides significant upfront capital, shared development burden, and global commercialization reach, together with compelling Phase I clinical data for VIR-5500 showing dose-dependent deep PSA declines, radiographic responses (45% ORR in RECIST-evaluable at high doses), limited high-grade CRS, and encouraging durability signals. Financial discipline improved in 2025 (R&D down 10%, SG&A down 23%, net loss reduced ~16%), and the company reports a strengthened cash position and runway into Q2 2028 when incorporating recent agreements. Key risks remain: the dataset is still early and relatively small, there are isolated higher-grade safety events (including two blurred-vision treatment-related discontinuations and one early Grade 3 CRS), certain payments are subject to third-party obligations and regulatory waiting periods, and continued dose optimization and longer follow-up are needed to confirm durability and broader applicability. Overall, the positives (deal, clinical signal, safety profile, financial improvements) substantially outweigh the current lowlights, though execution and maturation of data remain critical.Positive Updates
Strategic Collaboration with Astellas
Vir announced a global co-development and co-commercialization collaboration with Astellas for VIR-5500. Key terms include $315M upfront (comprised of $240M cash and $75M equity at $10.36/share), a $20M manufacturing tech-transfer milestone expected by mid-2027, up to $1.37B in additional development/regulatory/ex-U.S. commercial milestones, and total potential combined upfront and milestone payments of $1.7B. U.S. profits to be split 50/50; Vir has an option to co-promote in the U.S.; Astellas has exclusive ex-U.S. rights while Vir is entitled to tiered double-digit royalties and sales milestones; global development costs shared 40% Vir / 60% Astellas. Closing is subject to Hart-Scott-Rodino waiting period.
Negative Updates
Small, Early and Heavily Pretreated Clinical Dataset
Phase I dataset remains relatively small and immature: 58 patients overall, with key efficacy summaries from subsets (e.g., 11 RECIST-evaluable at ≥3,000 µg/kg). Many high-dose cohorts are still maturing and several patients remain early in treatment, making long-term durability and broader generalizability uncertain.
Read all updates
Q4-2025 Updates
Positive
Negative
Strategic Collaboration with Astellas
Vir announced a global co-development and co-commercialization collaboration with Astellas for VIR-5500. Key terms include $315M upfront (comprised of $240M cash and $75M equity at $10.36/share), a $20M manufacturing tech-transfer milestone expected by mid-2027, up to $1.37B in additional development/regulatory/ex-U.S. commercial milestones, and total potential combined upfront and milestone payments of $1.7B. U.S. profits to be split 50/50; Vir has an option to co-promote in the U.S.; Astellas has exclusive ex-U.S. rights while Vir is entitled to tiered double-digit royalties and sales milestones; global development costs shared 40% Vir / 60% Astellas. Closing is subject to Hart-Scott-Rodino waiting period.
Read all positive updates
Company Guidance
The company provided clear development and financial guidance: as of the Jan 9, 2026 cutoff the Phase I program had enrolled 58 mCRPC patients (median 4 prior lines, up to 7; 95% prior taxane; 93% bone mets, 45% visceral, 18% liver mets) with weekly and Q3W dosing up to a 4,000 µg/kg maintenance cohort and no DLTs; Vir has selected a go‑forward maintenance dose in the ~3,000–3,500 µg/kg range (no prophylactic steroids/IL‑6 planned), will open expansion cohorts in Q2 2026 (late‑line mCRPC monotherapy, 1L mCRPC combo, mHSPC combo) and aims for Phase III in 2027 while continuing dose optimization per Project Optimus. Efficacy/safety metrics at ≥3,000 µg/kg include 82% PSA50, >50% PSA90, ~33% PSA99, 11 RECIST‑evaluable patients with a 45% ORR (4 confirmed, 1 pending) and 64% disease control rate, durability to 27 weeks (individuals ~12 months), limited CRS (all low grade at ≥3,000; one earlier Grade 3 CRS on intra‑patient escalation), grade ≥3 treatment‑related AEs in 12% and 2 discontinuations. The Astellas collaboration provides $315M upfront ($240M cash + $75M equity at $10.36/sh), a $20M tech‑transfer milestone (mid‑2027), up to $1.37B additional milestones (total $1.7B potential), 50/50 U.S. profit split (Vir option to co‑promote), 40/60 global development cost share (Vir/Astellas), ex‑U.S. tiered double‑digit royalties, and—together with Norgine receipts—leaves Vir with ~$782M cash at start of 2026 and an expected runway into Q2 2028.Vir Biotechnology Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 68.56M | 74.20M | 86.18M | 1.62B | 1.10B |
| Gross Profit | 56.85M | -404.44M | -486.65M | 994.83M | 581.54M |
| EBITDA | -426.09M | -508.91M | -641.64M | 839.85M | 426.56M |
| Net Income | -437.99M | -521.96M | -615.06M | 515.84M | 528.58M |
Balance Sheet | |||||
| Total Assets | 1.00B | 1.40B | 1.92B | 2.80B | 1.95B |
| Cash, Cash Equivalents and Short-Term Investments | 462.86M | 905.35M | 1.52B | 2.40B | 708.14M |
| Total Debt | 186.91M | 97.89M | 124.54M | 127.97M | 137.49M |
| Total Liabilities | 237.55M | 248.43M | 328.82M | 724.13M | 522.42M |
| Stockholders Equity | 765.28M | 1.15B | 1.59B | 2.08B | 1.43B |
Cash Flow | |||||
| Free Cash Flow | -396.61M | -453.65M | -800.36M | 1.60B | -69.41M |
| Operating Cash Flow | -391.78M | -446.35M | -778.78M | 1.66B | -47.59M |
| Investing Cash Flow | 310.37M | 499.37M | 164.73M | -1.19B | -140.81M |
| Financing Cash Flow | 3.79M | 4.39M | 7.38M | 34.76M | 100.33M |
Vir Biotechnology Technical Analysis
Positive
9.83
Price Trends
8.63
Positive
7.43
Positive
6.38
Positive
Market Momentum
0.17
Negative
62.67
Neutral
86.64
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIR, the sentiment is Positive. The current price of 9.83 is above the 20-day moving average (MA) of 9.13, above the 50-day MA of 8.63, and above the 200-day MA of 6.38, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 62.67 is Neutral, neither overbought nor oversold. The STOCH value of 86.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VIR.
Vir Biotechnology Risk Analysis
Vir Biotechnology disclosed 58 risk factors in its most recent earnings report. Vir Biotechnology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vir Biotechnology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.57B | -1.91 | -49.31% | ― | -78.55% | 7.74% | |
59 Neutral | $1.12B | -25.24 | -12.63% | ― | 2147.20% | -269.99% | |
58 Neutral | $1.65B | -2.50 | -54.54% | ― | 175.62% | 19.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.06B | -3.56 | 536.36% | ― | -12.52% | -82.84% | |
46 Neutral | $282.65M | -13.95 | -38.76% | ― | ― | -5.71% | |
43 Neutral | $918.93M | -42.71 | -14.58% | ― | 38.16% | 48.43% |
* Healthcare Sector Average
VIR
Vir Biotechnology
9.83
4.26
76.48%
XNCR
Xencor
12.42
3.48
38.93%
IOVA
Iovance Biotherapeutics
3.70
0.29
8.50%
AVXL
Anavex Life Sciences
2.95
-5.87
-66.55%
IVA
Inventiva
5.50
2.21
67.22%
SEPN
Septerna, Inc.
24.83
18.76
309.06%
Vir Biotechnology Corporate Events
Business Operations and StrategyExecutive/Board Changes
Vir Biotechnology Names CEO Marianne De Backer as President
Positive
Mar 4, 2026
On March 4, 2026, Vir Biotechnology, Inc. expanded the responsibilities of Chief Executive Officer and principal executive officer Marianne De Backer by appointing her to the additional role of President. The company reported that there were no sp...
Private Placements and FinancingRegulatory Filings and Compliance
Vir Biotechnology Raises Capital Through Public Stock Offering
Positive
Mar 2, 2026
Vir Biotechnology, Inc. completed a public equity offering of common stock that was initially disclosed in a regulatory filing in late February 2026. The biopharmaceutical company sold shares at $8.50 each, underscoring its continued reliance on c...
Private Placements and FinancingRegulatory Filings and Compliance
Vir Biotechnology Announces Significant Common Stock Offering
Positive
Feb 27, 2026
On February 25, 2026, Vir Biotechnology, Inc. entered into an underwriting agreement with a syndicate of investment banks to offer 17,647,059 shares of its common stock at $8.50 per share. The transaction, conducted under an effective shelf regist...
Business Operations and StrategyPrivate Placements and Financing
Vir Biotechnology, Astellas Forge Major Prostate Cancer Alliance
Positive
Feb 23, 2026
On February 19, 2026, Vir Biotechnology and Astellas US LLC signed a collaboration and license agreement for VIR-5500, a PRO-XTEN dual-masked T-cell engager targeting PSMA that is in Phase 1 development for advanced prostate cancer. The deal, join...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Vir Biotechnology advances hepatitis delta program and cash runway
Positive
Jan 12, 2026
On January 12, 2026, Vir Biotechnology reported updated positive Phase 2 SOLSTICE data in chronic hepatitis delta showing that combination therapy with tobevibart and elebsiran achieved undetectable HDV RNA in 88% of evaluable participants at Week...
Business Operations and StrategyProduct-Related Announcements
Vir Biotechnology Secures Licensing Deal with Norgine
Positive
Dec 16, 2025
On December 16, 2025, Vir Biotechnology entered into a license agreement with Norgine Pharma UK Limited, granting Norgine exclusive commercial rights to a combination treatment for chronic hepatitis delta (CHD) in Europe, Australia, and New Zealan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.